Stockscreener 앱 받기
3.78
4.55%
-0.18
시장 영업 전:
3.71
-0.07
-1.85%
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits
Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wave Life Sciences Initiates Phase 2a Trial of Obesity Drug WVE-007 in Combination With Tirzepatide - marketscreener.com
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Wave Life Sciences starts Phase 2a obesity trial for WVE-007 - Investing.com India
Wave Life Sciences starts Phase 2a obesity trial for WVE-007 By Investing.com - Investing.com South Africa
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity - GlobeNewswire
JPMorgan resumes Wave Life Sciences stock rating at Neutral By Investing.com - Investing.com Australia
JPMorgan resumes Wave Life Sciences stock rating at Neutral - Investing.com
Wave Life Sciences stock hits a 52-week low at USD 4.20 - AD HOC NEWS
Wave Life Sciences Names Monika Vnuk Chief Business Officer - citybiz
Wave Life Sciences appoints Monika Vnuk as chief business officer By Investing.com - Investing.com Australia
Wave Life Sciences appoints Monika Vnuk as chief business officer - Investing.com
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - manilatimes.net
Wave Life Sciences Appoints Monika Vnuk as Chief Business Officer - Quiver Quantitative
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Nigeria
Wave Life Sciences at Cantor conference: RNA editing gains traction - investing.com
WAVE Life Sciences (WVE) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Wave Life Sciences Ltd. (WVE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Wave Life Sciences stock holds steady ahead of Cantor healthcare conference appearance - ad-hoc-news.de
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - GlobeNewswire
WVE Q2 2026 Earnings: Wider-Than-Expected Net Loss Triggers 2.97% SlideTangible Book Value - careplusvn.com
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
WVE Q2 2026 Earnings: EPS Misses Estimates as Clinical-Stage RNA Pipeline Investment ContinuesEarnings Trend Analysis - dars.gov.et
Wave Life Sciences stock trades quietly as investors focus on recent clinical progress - AD HOC NEWS
Wave Life Sciences Ltd. (WVE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold" - MarketBeat
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits
Wave Life Sciences targets fat loss without sacrificing muscle - Longevity.Technology
Insiders Sold Wave Life Sciences Prematurely At US$13.64 With Stock Trading Higher - Moomoo
Wave Life Sciences (WVE) Pulls Back 5.2% to $5.13 as Support Holds at $4.87Thematic ETF Flow - vinanet.vn
Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026) - Stock Titan
Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones - Stock Traders Daily
Wave Life Sciences, Inc.: Top Mutual Funds Holders | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Target Price Consensus and Analysts Recommendations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Performance & Quotes, WVE Stock Price on Nasdaq Exchange - marketscreener.com
Wave Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Financial Data Forecasts Estimates and Expectations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc. Stock (WVE)Quote Nasdaq - marketscreener.com
Q1 2025 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
WAVE Life Sciences Ltd at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Q2 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Wave Life Sciences Ltd.: Revenue and Earnings Analysts Forecasts Revisions | WVE | US94352A1043 - marketscreener.com
WVE Q2 2026 Earnings: Wider-than-Expected Loss of $0.34 per Share Highlights Pipeline InvestmentQuarterly Profit Report - careplusvn.com
Wave Life Sciences (WVE) Director Adrian Rawcliffe Sells 12,700 Shares, Reducing Stake to Zero - GuruFocus
WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares - MarketBeat
Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
Wave Life Sciences (WVE) director’s 3,864-share tax sale under 10b5-1 plan - Stock Titan
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover - Yahoo Finance
Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales - simplywall.st
Wave Life Sciences Ltd. SEC Filing (Aug 12, 2026) - Stock Titan
Wave Life Sciences at canaccord growth conference: obesity and RNA bets - Investing.com Canada
3.06%
2.55%
자본화:
|
볼륨(24시간):